Literature DB >> 8253698

Valproate oral loading in the treatment of acute mania.

P E Keck1, S L McElroy, K C Tugrul, J A Bennett.   

Abstract

BACKGROUND: Evidence from earlier studies suggests that the antimanic activity of valproate becomes most pronounced within 1 to 4 days of achieving serum concentrations of 50 mg/L or greater. We conducted a prospective study to assess the onset of antimanic activity of oral loading dosages of valproate administered to achieve serum concentrations above 50 mg/L within 24 hours.
METHOD: Nineteen patients with bipolar disorder, manic phase, received divalproex sodium 20 mg/kg/day in divided dosages for 5 days, without other psychotropic agents except lorazepam up to 4 mg/day. Serum valproate concentrations were measured after 1 and 4 days of treatment. Improvement was measured daily by a blind rater using the Young Mania Rating Scale (MRS).
RESULTS: Serum valproate concentrations greater than 50 mg/L were reached in all 15 patients completing the study. Ten (53%) of the 19 patients who received at least one complete loading dose displayed a significant (greater than 50%) reduction in MRS scores by study termination. These responders displayed the greatest percent change in MRS scores over the first 3 days of treatment. Side effects were minimal.
CONCLUSION: Valproate can be safely administered by oral loading and may produce rapid onset of antimanic response in some patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8253698

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

1.  Definitive treatment in the psychiatric emergency service.

Authors:  M H Allen
Journal:  Psychiatr Q       Date:  1996

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

3.  A Naturalistic, Single-blind Comparison of Rapid Dose Administration of Divalproex ER Versus Quetiapine in Patients with Acute Bipolar Mania.

Authors:  David Feifel; Barbara Galangue; Kai Macdonald; Patrice Cobb; Ana Dinca; Olga Becker; J Cooper; Allison Hadley
Journal:  Innov Clin Neurosci       Date:  2011-01

Review 4.  Comparative efficacy and tolerability of drug treatments for bipolar disorder.

Authors:  S M Strakowski; M P DelBello; C M Adler
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Effect size of lithium, carbamazepine, and sodium valproate in child and adolescent bipolar 1 disorder during manic phase: A prospective open-label study.

Authors:  Rakesh Kumar Singh; Vinod Kumar Sinha; Suprakash Chaudhury
Journal:  Ind Psychiatry J       Date:  2020-08-14

6.  Adolecsent mania, EEG abnormality and response to anticonvulsants: a three - year follow-up study.

Authors:  T K Aich; V K Sinha; H S Nizami
Journal:  Indian J Psychiatry       Date:  2001-07       Impact factor: 1.759

Review 7.  Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy.

Authors:  Cecilie Johannessen Landmark
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Anticonvulsant Use in the Treatment of Bipolar Disorder: A Primer for Primary Care Physicians.

Authors:  Raphael J. Leo; Rajesh Narendran
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-06

9.  Anticonvulsant drugs in bipolar disorder.

Authors:  H Grunze; S Schlösser; B Amann; J Walden
Journal:  Dialogues Clin Neurosci       Date:  1999-06       Impact factor: 5.986

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.